Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 02, 2025, titled "Zydus launches VaxiFluTM India s first trivalent influenza vaccine for flu protection".
Press Release Sep 02 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This vaccine aligns with the World Health Organization's recommendations for the upcoming flu season, addressing a significant global health concern. The launch aims to improve preventive health measures against seasonal influenza, particularly for vulnerable populations. Dr. Sharvil Patel emphasized the importance of timely access to vaccines to reduce vaccine-preventable diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 29 2025
- Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
- Press Release 20-08-2025 Newspaperadvertisement20082025
- Press Release Aug 13 2025
- Press Release Aug 12 2025
Later from Zydus Lifesciences
- Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market
- Press Release Sep 04 2025
- Press Release Sep 05 2025
- Press Release Sep 15 2025
- Zydus Lifesciences Limited Press Release Sep 21 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences